Alex Dusek

Dusek is leading the commercialization charge at Polarean, Inc. and has a deep background in bringing new medical technologies to market. When HIV/AIDS therapeutics was rapidly changing in the mid 1990s, he worked on the successful launch of several first-in-class antiviral medications at both Boehringer Ingelheim Pharmaceuticals and Trimeris. In the 2000s, he led the market introductions of several pulmonary medicines. At United Therapeutics he led the successful launch of Adcirca (tadalafil), which overtook Pfizer’s Sildenafil as the market leader in the PDE5-inhibitor class in Pulmonary Arterial Hypertension. Then, at Bayer Healthcare, Dusek led the global brand strategy for the worldwide Adempas (riociguat) launch and the medical education initiatives for ventilation/perfusion imaging for Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Dusek received an undergraduate degree from the College of William and Mary, completed post-baccalaureate studies at Columbia University, and an MBA from the Kenan-Flagler Business School at the University of North Carolina Chapel Hill.